gynecolog
malign
includ
ovarian
endometri
vulvar
fallopian
tube
cervic
cancer
lead
caus
mortal
women
cancer
relat
death
women
lethal
malign
ovarian
cancer
mani
factor
caus
gynecolog
cancer
although
oncogen
tumor
suppressor
gene
promot
growth
cancer
almost
cervic
cancer
cancer
vagina
vulva
caus
viru
known
human
papillomaviru
hpv
develop
prevent
vaccin
limit
infect
transmiss
hpv
work
primarili
induct
viru
neutral
antibodi
tremend
posit
step
forward
abl
use
therapeut
moreov
also
licens
vaccin
target
treat
gynecolog
malign
ovarian
cancer
high
level
tumor
infiltr
cell
associ
increas
surviv
patient
divers
gynecolog
malign
notabl
ovarian
cancer
emerg
immunotherapi
reestablish
full
function
cell
local
tumor
microenviron
base
primarili
disrupt
immunosuppress
interact
show
great
promis
multipl
clinic
trial
tout
gamechang
cancer
treatment
advanc
bring
renew
interest
develop
practic
method
increas
initi
cell
number
relev
tumor
antigen
vaccin
addit
major
emerg
trend
cancer
immunotherapi
abil
use
highthroughput
analysi
omic
techniqu
transcriptom
defin
tumor
subtyp
cancer
cell
heterogen
find
use
identifi
subtyp
henc
patient
abl
respond
clinic
specif
chemotherapi
aspect
precis
person
medicin
omic
techniqu
also
result
databas
rich
antigen
sequenc
potenti
abl
defin
best
target
antigen
express
cancer
cell
within
patient
develop
person
vaccin
peptid
offer
practic
sourc
antigen
person
therapeut
cancer
vaccin
induc
high
level
cell
also
noninfecti
complet
defin
rel
easi
produc
gener
consid
safe
design
peptidebas
vaccin
particularli
involv
new
gener
nanoparticlebas
deliveri
system
involv
challeng
ensur
correct
antigen
process
mhc
class
mhc
restrict
epitop
promot
cell
prime
controversi
remain
literatur
natur
peptid
use
vaccin
context
cancer
rang
peptid
repres
minim
nativ
cell
epitop
agonist
variant
help
break
potenti
toler
enhanc
mhc
bind
immunogen
peptid
repres
weak
natur
epitop
minim
peptid
epitop
ad
amino
acid
either
end
promot
stabil
microenviron
contain
exopeptidas
well
potenti
promot
appropri
cleavag
process
minim
epitop
coval
conjug
nanoparticl
inclus
cell
epitop
either
replic
peptid
region
protein
contain
cell
epitop
construct
artifici
construct
encompass
one
peptid
contain
epitop
differ
protein
context
anoth
limit
peptidebas
vaccinesimmunotherapi
need
immun
domin
epitop
match
patient
human
leukocyt
antigen
hla
hla
polymorph
patient
make
difficult
develop
peptidebas
vaccin
broadli
applic
across
patient
popul
usual
low
immunogen
cancer
associ
antigen
often
overexpress
variant
selfantigen
also
need
select
power
vaccin
adjuv
carrier
abl
promot
strong
immun
respons
previou
report
nanoparticl
specif
size
nm
induc
strong
immun
respons
coval
link
antigen
platform
technolog
specif
size
defin
polystyren
nanoparticl
psnp
shown
power
selfadjuv
properti
use
deliv
protein
model
antigen
ovalbumin
ova
dna
plasmid
express
ova
well
high
affin
peptid
includ
strong
antigen
respiratori
syncyti
viru
rsv
malaria
liver
stage
antigen
studi
psnp
show
superior
adjuvanc
convent
proinflammatori
adjuv
aluminum
hydroxid
alum
quil
monophosphoryl
lipid
mpl
induct
antigen
specif
cell
cell
particularli
produc
cell
well
long
last
antibodi
level
uniqu
featur
psnp
adjuv
system
contrast
adjuv
work
promot
inflamm
via
tolllikereceptor
tlr
pathogenrecognitionreceptor
prr
signal
psnp
induc
convent
inflamm
mediat
erk
akt
signal
induct
convent
proinflammatori
cytokin
tnf
expans
inflamm
reactiv
regulatori
cell
treg
featur
could
make
system
similar
properti
particularli
use
develop
cancer
therapeut
vaccin
inflamm
treg
induct
associ
tumor
progress
furthermor
psnpspeptid
vaccin
formul
also
shown
protect
therapeut
efficaci
variou
murin
tumor
model
multipl
divers
peptid
antigen
unpublish
howev
major
challeng
translat
remain
understand
rule
select
use
peptid
appropri
process
present
stimul
cell
immun
paper
specif
explor
challeng
test
differ
peptid
formul
transgen
anim
hypothes
psnp
could
effect
link
coval
conjug
peptid
antigen
deriv
gynecolog
tumor
gener
immunogen
construct
capabl
induc
restrict
cell
moreov
herein
explor
divers
formul
challeng
use
peptid
vaccin
gener
specif
differ
process
minim
cell
epitop
use
nanoparticlebas
vaccin
psnp
explor
issu
studi
divers
peptid
deriv
three
differ
antigen
associ
major
divers
gynecolog
malign
protein
demonstr
major
target
cell
cervic
cancer
survivin
sv
oncogen
inhibitorofapoptosi
protein
express
cervic
ovarian
malign
will
tumor
antigen
wellstudi
antigen
context
divers
tumor
type
leukemia
ovarian
cancer
review
recent
list
among
top
ideal
cancer
antigen
immunotherapi
us
nation
cancer
institut
tabl
list
peptid
synthes
studi
peptid
synthes
auspep
tullamarin
vic
australia
peptid
synthes
cs
bio
menlo
park
ca
unit
state
puriti
ident
peptid
determin
hplc
mass
spectrometri
respect
select
antigen
peptid
tabl
chosen
peptidebas
vaccin
target
form
nanovaccin
formul
individu
peptid
coval
conjug
nm
carboxyl
polystyren
nanoparticl
psnp
polysci
inc
warrington
pa
unit
state
form
peptidepsnp
vaccin
formul
eg
etc
peptid
conjug
optim
peptid
order
achiev
best
conjug
effici
size
brief
follow
conjug
procedur
describ
previous
psnp
final
solid
preactiv
gentli
mix
rotat
wheel
h
room
temperatur
mixtur
contain
acid
me
mm
final
ph
carbodiimid
hydrochlorid
edc
mgml
final
sigmaaldrich
st
loui
unit
state
nhydrosulfosuccinimid
sulfonh
mm
final
thermo
fisher
scientif
waltham
unit
state
final
ph
adjust
preactiv
excess
activ
agent
edc
sulfonh
remov
preactiv
mix
use
gel
filtrat
column
zeba
spin
desalt
column
follow
manufactur
instruct
thermo
fisher
scientif
buffer
exchang
time
via
column
buffer
concentr
ph
optim
peptid
antigen
ad
peptid
antigen
h
final
conjug
mix
dialys
phosphat
buffer
pb
ph
kda
dialysi
membran
nonpb
buffer
use
conjug
buffer
final
conjug
effici
determin
protein
assay
micro
bca
protein
assay
thermo
fisher
scientif
amino
acid
analysi
via
hplc
perform
auspep
particl
size
polydispers
final
peptid
conjug
psnp
peptidepsnp
formul
measur
dynam
light
scatter
zetas
malvern
instrument
ltd
worcestershir
unit
kingdom
vaccin
dose
contain
peptid
solid
psnp
pb
amount
peptid
antigen
inject
match
formul
adjust
inject
volum
experi
formul
directli
compar
bench
mark
adjuv
cpg
direct
mix
test
peptid
cpg
odn
invivogen
san
diego
ca
unit
state
vaccin
studi
carri
accord
recommend
institut
guidelin
anim
welfar
assur
act
alfr
medic
research
educ
precinct
amrep
protocol
approv
amrep
anim
ethic
committe
melbourn
australia
immunogen
peptidepsnp
vaccin
formul
test
transgen
mice
anim
resourc
centr
western
australia
briefli
mice
immun
test
formul
multipl
time
per
experiment
design
intraderm
id
base
tail
week
apart
per
experiment
design
detail
immun
schedul
list
respect
figur
legend
ten
fourteen
day
follow
last
immun
mice
euthan
asphyxi
spleen
remov
splenocyt
harvest
test
antigen
specif
immunogen
enzymelink
immunospot
elispot
assay
antigen
specif
cell
respons
evalu
elispot
assay
briefli
filtrat
plate
maha
msip
maip
plate
millipor
billerica
coat
antimous
mabtech
stockholm
sweden
follow
overnight
incub
well
wash
block
rpmi
complet
medium
cm
supplement
heat
inactiv
fetal
bovin
serum
fb
mm
glutamin
streptomycin
unitsml
penicillin
mm
mm
hepe
gibco
life
technolog
ca
unit
state
splenocyt
immun
mice
cellsml
either
individu
pool
ad
triplic
well
incub
recal
antigen
see
figur
legend
specif
detail
respect
experi
variou
concentr
final
potenti
epitop
final
long
peptid
protein
incub
fill
minimum
h
concanavalin
cona
final
amersham
bioscienc
uppsala
sweden
use
posit
control
background
well
ad
cm
plate
wash
time
pb
incub
biotinyl
detect
antibodi
antimous
biotinyl
mab
mabtech
final
room
temperatur
h
wash
streptavidinalkalin
phosphatas
ad
final
incub
anoth
h
room
temperatur
plate
wash
final
wash
use
revers
osmosi
ro
water
remov
residu
pb
spot
develop
use
colorimetr
ap
kit
biorad
philadelphia
usa
follow
manufactur
instruct
spot
count
perform
use
aid
elispot
reader
system
autoimmun
diagnostika
gmbh
germani
magnitud
induct
respons
recal
antigen
compar
either
directli
spot
form
unit
sfu
normal
background
respons
media
alon
respons
treatment
group
calcul
stimul
index
si
sfu
background
si
sfu
recal
antigen
stimul
mice
treatment
sfu
media
alon
stimul
mice
treatment
correspond
recal
antigen
statist
analys
perform
use
graph
pad
prism
softwar
graph
pad
softwar
inc
la
jolla
ca
unit
state
microsoft
excel
microsoft
corpor
redmond
wa
unit
state
comparison
perform
use
one
twoway
anova
analysi
appropri
differ
consid
statist
signific
p
valu
express
mean
standard
deviat
sd
hpv
type
respons
cervic
cancer
protein
amino
acid
aa
highli
immunogen
good
indic
clinic
relev
immunogen
cervic
cancer
base
extens
literatur
search
clinic
trial
manufactur
feasibl
well
aid
epitop
predict
program
predict
algorithm
syfpeithi
databas
http
wwwsyfpeithid
design
final
three
hpv
peptid
candid
nanovaccin
target
tabl
minim
cell
epitop
chimer
peptid
consist
two
cell
epitop
cell
helper
construct
peptid
fragment
contain
helper
epitop
two
cell
epitop
also
design
peptid
contain
promiscu
cell
epitop
helper
peptid
incorpor
nanovaccin
formul
necessari
develop
procedur
coval
link
peptid
antigen
nanoparticl
produc
uniformli
size
singl
layer
antigen
attach
nanovaccin
formul
conjug
process
requir
use
activ
agent
carbodiimid
hydrochlorid
edc
nhydroxysulfosuccinimid
sulfonh
cleav
carboxyl
group
creat
intermedi
amin
reactiv
ester
bond
allow
coval
coupl
peptideprotein
nanoparticl
best
achiev
condit
ph
howev
ph
peptid
insolubl
form
peptidespsnp
aggreg
subsequ
suitabl
nanovaccin
formul
particl
size
crucial
particleadjuvanc
therefor
base
standard
procedur
see
materi
method
section
alter
conjug
condit
conjug
step
test
rang
ph
buffer
pb
peptid
candid
ensur
high
conjug
effici
well
minim
aggreg
sinc
peptid
physiochem
characterist
qualiti
peptid
conjug
nanoparticl
formul
peptidepsnp
determin
size
polydispers
index
pdl
well
conjug
effici
antigen
load
per
particl
conjug
hpv
peptid
psnp
test
pb
variou
ph
result
shown
figur
lower
ph
conjug
step
hpv
peptid
psnp
formul
tend
aggreg
increas
size
though
aggreg
reduc
increas
ph
optim
ph
final
ph
rang
gener
accept
size
hpv
peptid
psnp
conjug
select
basi
condit
produc
particleconjug
rang
nm
nanoparticl
polydispers
pdl
tabl
determin
conjug
effici
select
optim
buffer
ph
conjug
condit
peptid
test
remain
nonbind
peptid
materi
formul
conjug
process
determin
protein
assay
analysi
via
hplc
possibl
final
conjug
effici
determin
percentag
antigen
success
conjug
psnp
target
antigen
concentr
mgml
antigen
peptid
tabl
summar
optim
conjug
condit
hpv
peptid
candid
evalu
studi
peptid
repres
nativ
minim
cell
epitop
achiev
highest
antigen
load
per
psnp
peptid
moleculesparticl
compar
peptid
peptid
load
peptid
load
consist
match
amount
antigen
across
experiment
group
use
immunogen
studi
hpv
peptidebas
nanovaccin
formul
inject
differ
group
transgen
mice
id
base
tail
evalu
immunogen
hpv
minim
cell
epitop
tlgivcpi
peptid
alon
first
test
capac
induc
antigen
specif
cell
respons
mice
directli
conjug
psnp
mix
togeth
cpg
withwithout
addit
peptid
cell
epitop
peptid
select
predict
capac
induc
mhc
class
ii
restrict
immun
either
mice
human
tabl
result
show
one
immun
either
mix
cpg
conjug
psnp
alon
induc
antigen
specif
cell
respons
figur
upon
mix
addit
cell
helper
epitop
high
product
observ
cell
peptid
epitop
cell
respons
could
elicit
figur
result
indic
hpv
minim
cell
epitop
alon
ad
cell
help
capabl
provok
antigen
specif
cell
respons
consist
long
peptid
antigen
includ
cell
epitop
differ
surround
amino
acid
context
includ
differ
epitop
sequenc
tabl
nanovaccin
formul
either
two
peptid
conjug
psnp
use
immun
anim
mice
antigen
specif
respons
cell
epitop
observ
upon
vaccin
transgen
mice
even
one
immun
figur
indic
minim
cell
epitop
tlgivcpi
contain
effici
process
present
molecul
contrast
formul
cpg
either
two
peptid
elicit
cell
tlgivcpispecif
respons
despit
gener
immunogen
fulllength
sequenc
figur
data
suggest
differ
antigen
process
cpg
nanovaccin
cell
epitop
case
identifi
suitabl
peptid
target
use
develop
peptid
base
nanovaccin
elicit
respons
cancer
induc
explor
potenti
chang
immun
schedul
improv
potenc
nanovaccin
formul
specif
assess
impact
chang
time
interv
immun
figur
transgen
mice
inject
batch
id
base
tail
follow
schedul
overal
level
immun
respons
nativ
epitop
immunogen
gener
increas
addit
immunis
schedul
weekli
immunis
figur
although
immunis
also
similar
inject
overal
induct
immun
respons
immun
schedul
produc
consist
level
less
mousetomous
variabl
immun
respons
immun
schedul
clearli
show
shorten
time
immun
day
detriment
cell
immun
respons
induct
upon
hpvpsnp
vaccin
cell
respons
exhaust
might
even
benefici
therefor
intraderm
immun
induc
antigenspecif
respons
minim
cell
epitop
transgen
mice
increas
number
immunis
posit
increas
overal
immun
respons
strongest
immun
respons
observ
weekli
immun
wilm
tumor
antigen
shown
highli
express
play
oncolog
role
variou
hematolog
solid
malign
neglig
express
normal
tissu
thu
make
ideal
target
cancer
immunotherapi
strategi
list
among
top
ideal
cancer
antigen
immunotherapi
us
nation
cancer
institut
human
peptidebas
vaccin
epitop
well
character
literatur
elicit
cell
respons
adult
children
cancer
patient
allel
although
cell
respons
toward
epitop
rmfpnapyl
herein
call
tabl
identifi
variou
cancer
patient
research
clinic
trial
use
peptid
vaccin
strategi
disappoint
cell
respons
either
shortliv
repeat
vaccin
enrich
lower
avid
popul
could
expand
vitro
may
function
impair
follow
vaccin
modifi
version
substitut
arginin
r
tyrosin
posit
ymfpnapyl
herein
call
tabl
shown
increas
peptid
bind
stabil
molecul
shown
recogn
nativ
human
previou
studi
also
demonstr
vaccin
adjuv
cpg
gener
function
similar
cell
respons
cognat
antigen
ex
vivo
vaccin
regimen
could
readili
expand
respons
cognat
peptid
gener
greater
cell
respons
show
greater
potenti
gener
proport
dual
respons
crossreact
could
expand
peptid
potenti
promot
better
respons
would
abl
crossreact
nativ
epitop
base
find
design
variant
peptid
could
contain
within
extend
peptid
tabl
conjug
psnp
form
peptidepsnp
nanovaccin
formul
evalu
abil
induc
antigen
specif
cell
respons
case
also
extend
sequenc
carboxi
amino
end
would
nativ
context
addit
follow
recent
literatur
suggest
flank
amino
acid
aromat
tyrosin
basic
lysin
k
small
aliphat
side
chain
alanin
support
effici
cytotox
lymphocyt
ctl
recognit
epitop
addit
aay
amino
acid
sequenc
includ
amino
end
gener
peptid
attempt
increas
cell
epitop
process
recognit
explor
provid
process
context
side
epitop
gener
plu
extens
carboxi
end
tabl
conjug
peptid
psnp
test
pb
variou
ph
rang
shown
figur
peptid
conjug
rang
ph
condit
pb
conjug
step
formul
aggreg
buffer
condit
stabl
ph
wherea
formul
stabl
aggreg
observ
ph
rang
test
therefor
optim
ph
rang
peptid
candid
peptid
conjug
psnp
ph
final
conjug
nanovaccin
formul
uniform
size
rang
nm
pdl
tabl
summar
optim
conjug
condit
peptid
candid
evalu
studi
overal
conjug
effici
excel
hplc
analysi
antigen
load
number
peptid
moleculesparticl
also
high
tabl
consist
match
amount
antigen
across
experiment
group
use
immunogen
studi
peptidebas
nanovaccin
formul
inject
transgen
mice
id
base
tail
evalu
immunogen
see
materi
method
section
figur
legend
detail
result
figur
show
intraderm
immun
formul
induc
antigenspecif
respons
cell
epitop
rmfpnapyl
nativ
sequenc
variant
ymfpnapyl
p
p
p
respect
despit
fact
formul
contain
cell
epitop
neglig
differ
cell
specif
respons
elicit
two
formul
although
trend
better
induct
antigenspecif
cell
respons
nativ
epitop
vaccin
anim
addit
amino
acid
sequenc
aay
flank
region
peptid
report
promot
appropri
process
recognit
minim
epitop
observ
studi
incorpor
sequenc
enhanc
respons
minim
epitop
even
decreas
crossreact
cell
respons
nativ
antigen
compar
induc
respons
formul
p
p
respect
figur
therefor
case
peptid
antigen
substitut
amino
acid
arginin
r
tyrosin
gener
strong
immun
respons
well
crossreact
respons
nativ
epitop
extend
minim
cell
epitop
incorpor
amino
acid
deriv
natur
context
predict
potenti
promot
process
enhanc
cell
immun
respons
induc
survivin
sv
oncogen
inhibitorofapoptosi
protein
aa
crucial
surviv
tumor
cell
gener
express
low
neglig
level
normal
tissu
express
wide
varieti
cancer
includ
lung
breast
pancreat
colorect
stomach
ovarian
tumor
well
hematolog
malign
fourth
highli
express
transcript
human
cancer
cell
found
overexpress
ovarian
cancer
make
potenti
good
target
vaccin
base
treatment
ovarian
cancer
howev
despit
fact
survivin
peptid
studi
multipl
clinic
trial
confirm
safeti
survivin
weakli
immunogen
henc
protect
across
studi
differ
choic
antigen
deliveri
adjuv
system
could
potenti
enhanc
immunogen
protein
cell
epitop
survivin
protein
import
induct
effect
antitumor
immun
respons
given
psnp
nanoparticl
vaccin
approach
success
deliv
peptid
antigen
see
previou
public
explor
increas
immunogen
lead
survivin
peptid
contain
cell
epitop
use
nanoparticl
formul
number
survivinderiv
candid
peptid
identifi
base
extens
literatur
search
clinic
trial
manufactur
feasibl
tabl
restrict
cell
nativ
epitop
peptid
mostli
cite
literatur
order
increas
minim
cell
epitop
bind
affin
allel
subsequ
increas
immun
respons
modifi
version
peptid
made
substitut
amino
acid
threonin
methionin
posit
elmlgeflkl
herein
name
agonist
use
psnp
vaccin
potenti
encourag
appropri
antigen
process
epitop
recognit
molecul
aay
amino
acid
sequenc
amino
flank
region
also
includ
aaylmlgeflkl
name
addit
panel
peptid
also
design
incorpor
cell
epitop
potenti
downstream
use
human
peptid
antigen
sequenc
evalu
immunogen
psnp
nanovaccin
formul
studi
tabl
contain
cell
epitop
cover
multipl
cell
epitop
well
cell
epitop
good
coverag
mhci
mhc
ii
recognit
contain
cell
epitop
promiscu
hladrrestrict
cell
epitop
variant
contain
multipl
cell
epitop
crossreact
promiscu
hladrrestrict
cell
epitop
conjug
survivin
peptid
psnp
test
pb
variou
ph
result
shown
figur
peptid
conjug
rang
ph
condit
pb
conjug
step
apart
formul
aggreg
buffer
condit
aggreg
reduc
increas
ph
optim
ph
formul
stabl
aggreg
ph
rang
test
therefor
optim
ph
rang
sv
peptid
candid
sv
peptid
conjug
psnp
ph
final
conjug
nanovaccin
formul
uniform
size
rang
nm
pdl
tabl
summar
optim
conjug
condit
sv
peptid
candid
evalu
studi
sv
peptid
abl
conjug
psnp
high
conjug
effici
ultim
high
level
antigen
load
repres
number
peptid
molecul
per
particl
tabl
consist
match
amount
antigen
across
experiment
group
use
immunogen
studi
survivin
peptidebas
nanovaccin
formul
inject
transgen
mice
id
base
tail
evalu
immunogen
see
materi
method
section
figur
legend
detail
long
peptid
contain
multipl
cell
epitop
well
minim
cell
epitop
variant
first
evalu
psnp
conjug
nanovaccin
formul
result
figur
show
peptid
conjug
psnp
mix
cpg
test
antigen
specif
immun
respons
recal
peptid
none
induc
antigen
specif
cell
respons
peptid
conjug
psnp
mix
cpg
test
recal
peptid
peptid
abl
induc
weak
respons
formul
si
p
compar
background
therefor
peptid
abl
substanti
cell
respons
nativ
restrict
epitop
respect
either
formul
conjug
psnp
adjuv
cpg
cell
mediat
respons
observ
recal
cell
epitop
respect
figur
howev
peptid
agonist
lmlgeflkl
peptid
epitop
natur
epitop
antigen
conjug
psnp
abl
gener
strong
respons
p
figur
respons
equival
elicit
cpg
adjuv
peptid
formul
meanwhil
weak
signific
respons
also
induc
peptid
formul
compar
group
p
p
cpg
psnp
group
respect
base
immunogen
peptid
formul
design
survivin
peptid
agonist
variant
agonist
variant
agonist
variant
extend
sequenc
aay
flank
region
potenti
help
increas
epitop
process
evalu
immunogen
conjug
psnp
shown
figur
howev
none
longer
peptid
contain
cell
survivin
deriv
natur
agonist
epitop
abl
induc
antigen
specif
cell
respons
contrast
cell
epitop
variant
contain
abl
induc
restrict
cell
respons
variant
upon
immun
vaccin
formul
figur
disappointingli
howev
none
nativ
agonist
formul
abl
induc
strong
natur
survivin
cell
epitop
comprehens
studi
assess
impact
minor
rel
chang
peptid
length
sequenc
induct
cell
respons
transgen
mice
antigen
relev
develop
gynecolog
cancer
vaccin
base
lead
vaccin
antigen
survivin
focus
specif
potenti
use
nanoparticlebas
vaccin
formul
psnp
minim
cell
peptid
epitop
elicit
signific
immun
use
convent
adjuv
cpg
deliv
conjug
psnp
nanoparticl
carrier
result
contrast
previou
studi
use
psnp
deliv
high
affin
minim
cell
epitop
siinfekl
ova
syipsaeki
plasmodium
berghei
circumsporozoit
protein
differ
antigen
load
would
explain
find
excel
load
nanoparticl
size
retent
immunogen
rang
compar
previou
studi
suggest
lower
affin
epitop
may
depend
cell
help
address
whether
observ
lack
respons
lack
cell
help
mix
known
hpv
deriv
cell
helper
epitop
howev
approach
facilit
cell
induct
contrast
specif
respons
elicit
sequenc
lengthen
amino
end
within
natur
context
includ
cell
epitop
use
formul
nanoparticl
base
vaccin
note
extend
sequenc
contrast
cpg
adjuv
elicit
respons
fulllength
peptid
fail
induc
cell
respons
like
deliv
extend
peptid
conjug
psnp
promot
uptak
help
intracellular
process
crossprim
dc
special
induct
cell
inde
previou
studi
psnp
shown
uptak
crossprim
dc
well
tap
depend
prime
cell
epitop
contain
psnpprotein
conjug
vaccin
indic
use
altern
intracellular
crossprim
process
pathway
furthermor
cell
respons
could
also
elicit
cell
prime
cultur
human
peripher
blood
mononuclear
cell
pbmc
unpublish
data
minim
bind
cell
epitop
protein
conjug
nanoparticl
psnp
similarli
fail
induc
cell
case
suffici
gener
high
affin
agonist
produc
bioactiv
vaccin
psnp
conjug
abl
induc
immun
respons
crossreact
result
suggest
mutat
antigen
deriv
describ
antigen
upon
conjug
nanoparticl
induc
higher
grade
immunogen
extend
sequenc
either
end
model
either
natur
peptid
context
incorpor
sequenc
aay
amino
end
describ
literatur
abl
promot
better
antigen
process
recognit
fail
enhanc
cell
respons
gener
vaccin
includ
formul
specif
case
therefor
optim
vaccin
may
simpli
minim
high
affin
agonist
cell
epitop
conjug
directli
nanoparticl
similarli
previou
studi
use
malaria
high
affin
agonist
peptid
psnp
similarli
initi
neg
result
observ
use
unmodifi
survivin
deriv
minim
cell
epitop
extend
peptid
length
alon
conjug
psnp
abl
rescu
cell
induct
particularli
weak
binder
mhc
class
known
difficult
epitop
level
endogen
toler
selfantigen
case
also
trial
test
super
agonist
variant
use
human
clinic
trial
context
adjuv
explor
potenti
util
nanoparticlebas
formul
similarli
observ
use
agonist
coupl
directli
nanoparticl
abl
induc
substanti
cell
respons
disappointingli
respons
crossreact
nativ
sequenc
extend
sequenc
within
natur
context
gener
longer
peptid
increas
broaden
even
decreas
reactiv
contrast
ad
aay
sequenc
amino
end
result
enhanc
immun
respons
enhanc
respons
accompani
broaden
reactiv
includ
crossreact
expand
spectrum
crossreact
may
explor
futur
studi
method
chang
amino
acid
sequenc
gener
complex
agonist
approach
use
success
expand
spectrum
recogn
variant
cell
epitop
circumsporozoit
protein
p
berghei
context
malaria
magnitud
immun
respons
induc
formul
present
studi
compar
previou
studi
shown
tumor
protect
divers
anim
model
unpublish
howev
vaccin
aim
induc
cell
realli
translat
certainti
obtain
high
tumor
protect
cell
respons
human
best
tumor
protect
studi
anim
even
transgen
anim
indic
vaccin
potenti
aim
studi
progress
particular
formul
human
trial
object
futur
import
perform
challeng
experi
appropri
transgen
model
togeth
find
present
herein
demonstr
nanoparticl
carrier
psnp
induc
convent
inflamm
capabl
gener
enhanc
cell
immun
respons
model
antigen
mice
vaccin
relev
restrict
peptid
epitop
multipl
protein
relev
gynecolog
cancer
furthermor
specif
peptid
epitop
psnp
nanovaccin
shown
elicit
cell
respons
even
strong
adjuv
fail
induc
respons
studi
howev
suggest
particularli
weak
natur
epitop
neither
convent
inflammatori
adjuv
cpg
nanoparticl
vaccin
approach
may
convert
strong
immunogen
necessari
optim
use
superagonist
epitop
sx
mp
cofound
director
px
biosolut
pti
ltd
sponsor
research
program
present
remain
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
